{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,7,13]],"date-time":"2026-07-13T00:12:43Z","timestamp":1783901563595,"version":"3.55.0"},"reference-count":26,"publisher":"Walter de Gruyter GmbH","issue":"1","license":[{"start":{"date-parts":[[2026,2,6]],"date-time":"2026-02-06T00:00:00Z","timestamp":1770336000000},"content-version":"unspecified","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2026,3,1]]},"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:sec>\n                    <jats:title>Background<\/jats:title>\n                    <jats:p>Growing evidence of safety and feasibility has prompted a shift toward ultra-hypofractionated (UHF) schedules in postoperative radiotherapy in early breast cancer.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Patients and methods<\/jats:title>\n                    <jats:p>Eighty patients over 50 years of age with early breast cancer (T1-2 and N0-1) who underwent postoperative, 3D conformal, free-breathing whole breast radiotherapy were included. The prospective arm consisted of 40 patients treated with UHF (26 Gy\/5 fractions\/one week) from 2023-2024, whereas the control arm was retrospective and represented by data from 40 patients treated with hypofractionated radiotherapy (HF) (40.5\u201342.2Gy\/15\u201316 fractions\/3 weeks) between 2015 and 2020. Dosimetric parameters for organs at risk (OARs) (heart and ipsilateral lung) were derived from the dose-volume histograms. Statistical evaluation was done with paired sample t-test and Mann-Whitney U test.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results<\/jats:title>\n                    <jats:p>\n                      Dosimetric analysis revealed that patients treated with UHF schedule received significantly lower equivalent doses in 2 Gy fractions (EQD\n                      <jats:sub>2<\/jats:sub>\n                      Gy) to OARs compared with those treated with the HF schedule. The mean ipsilateral lung EQD\n                      <jats:sub>2<\/jats:sub>\n                      Gy dose was significantly lower in the UHF group (3.94 \u00b1 2.1 Gy) than in the HF group (6.24 \u00b1 2.4 Gy;\n                      <jats:italic>p<\/jats:italic>\n                      &lt; 0.01). Among patients with left-sided breast cancer, the mean heart EQD\n                      <jats:sub>2<\/jats:sub>\n                      Gy dose was also significantly reduced in the UHF group (1.34 \u00b1 0.5 Gy) compared with the HF group (3.02 \u00b1 1.4 Gy;\n                      <jats:italic>p<\/jats:italic>\n                      &lt; 0.01).\n                    <\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusions<\/jats:title>\n                    <jats:p>These findings indicate a consistent dosimetric advantage of the UHF schedule, particularly in reducing radiation exposure to the heart and ipsilateral lung. These results support the dosimetric safety and feasibility of UHF schedules in early breast cancer treatment.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.2478\/raon-2026-0008","type":"journal-article","created":{"date-parts":[[2026,2,13]],"date-time":"2026-02-13T17:13:09Z","timestamp":1771002789000},"page":"124-131","source":"Crossref","is-referenced-by-count":1,"title":["Dosimetric comparison of organs at risk in ultra-hypofractionated versus hypofractionated postoperative radiotherapy for early breast cancer: single center clinical study"],"prefix":"10.2478","volume":"60","author":[{"given":"Gordana","family":"Petkovska","sequence":"first","affiliation":[{"name":"University Clinic for Radiotherapy and Oncology ,, Skopje , R. North Macedonia"},{"name":"Faculty of Medicine, University St. Cyril and Methodius , Skopje , R. North Macedonia"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ivica","family":"Ratosa","sequence":"additional","affiliation":[{"name":"Division of Radiotherapy, Institute of Oncology Ljubljana , Ljubljana , Slovenia"},{"name":"Faculty of Medicine, University of Ljubljana , Ljubljana , Slovenia"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Valentina Bojovska","family":"Trajanovska","sequence":"additional","affiliation":[{"name":"University Clinic for Radiotherapy and Oncology ,, Skopje , R. North Macedonia"},{"name":"Faculty of Medicine, University St. Cyril and Methodius , Skopje , R. North Macedonia"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Marina","family":"Iljovska","sequence":"additional","affiliation":[{"name":"University Clinic for Radiotherapy and Oncology ,, Skopje , R. North Macedonia"},{"name":"Faculty of Medicine, University St. Cyril and Methodius , Skopje , R. North Macedonia"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Albina Pupakovski","family":"Creslovnik","sequence":"additional","affiliation":[{"name":"University Clinic for Radiotherapy and Oncology ,, Skopje , R. North Macedonia"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Emilija","family":"Lazareva","sequence":"additional","affiliation":[{"name":"University Clinic for Radiotherapy and Oncology ,, Skopje , R. North Macedonia"},{"name":"Faculty of Medicine, University St. Cyril and Methodius , Skopje , R. North Macedonia"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"374","published-online":{"date-parts":[[2026,2,6]]},"reference":[{"key":"2026071216052977598_j_raon-2026-0008_ref_001","doi-asserted-by":"crossref","unstructured":"Sung H, Ferlay J, Siegel RL, Laversanne M, Soerjomataram I, Jemal A, et al. Global cancer statistics 2020: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries. CA Cancer J Clin 2021; 71: 209-49. doi: 10.3322\/caac.21660","DOI":"10.3322\/caac.21660"},{"key":"2026071216052977598_j_raon-2026-0008_ref_002","doi-asserted-by":"crossref","unstructured":"Heer E, Harper A, Escandor N, Sung H, McCormack V, Fidler-Benaoudia MM. Global burden and trends in premenopausal and postmenopausal breast cancer: a population-based study. Lancet Glob Health 2020; 8: e1027-37. doi: 10.1016\/s2214-109x(20)30215-1","DOI":"10.1016\/S2214-109X(20)30215-1"},{"key":"2026071216052977598_j_raon-2026-0008_ref_003","doi-asserted-by":"crossref","unstructured":"Arnold M, Morgan E, Rumgay H, Mafra A, Singh D, Laversanne M, et al. Current and future burden of breast cancer: global statistics for 2020 and 2040. Breast 2022; 66: 15-23. doi: 10.1016\/j.breast.2022.08.010","DOI":"10.1016\/j.breast.2022.08.010"},{"key":"2026071216052977598_j_raon-2026-0008_ref_004","doi-asserted-by":"crossref","unstructured":"Fisher B, Montague E, Redmond C, Deutsch M, Brown GR, Zauber A, et al. Findings from NSABP Protocol No. B-04-comparison of radical mastectomy with alternative treatments for primary breast cancer. I. Radiation compliance and its relation to treatment outcome. Cancer 1980; 46: 1-13. doi: 10.1002\/1097-0142(19800701)46:1<1::aid-cncr2820460102>3.0.co;2-3","DOI":"10.1002\/1097-0142(19800701)46:1<1::AID-CNCR2820460102>3.0.CO;2-3"},{"key":"2026071216052977598_j_raon-2026-0008_ref_005","doi-asserted-by":"crossref","unstructured":"Fisher B, Anderson S, Bryant J, Margolese RG, Deutsch M, Fisher ER, et al. Twenty-year follow-up of a randomized trial comparing total mastectomy, lumpectomy, and lumpectomy plus irradiation for the treatment of invasive breast cancer. N Engl J Med 2002; 347: 1233-41. doi: 10.1056\/nejmoa022152","DOI":"10.1056\/NEJMoa022152"},{"key":"2026071216052977598_j_raon-2026-0008_ref_006","doi-asserted-by":"crossref","unstructured":"Veronesi U, Cascinelli N, Mariani L, Greco M, Saccozzi R, Luini A, et al. Twenty-year follow-up of a randomized study comparing breast-conserving surgery with radical mastectomy for early breast cancer. N Engl J Med 2002; 347: 1227-32. doi: 10.1056\/nejmoa020989","DOI":"10.1056\/NEJMoa020989"},{"key":"2026071216052977598_j_raon-2026-0008_ref_007","doi-asserted-by":"crossref","unstructured":"van Leeuwen CM, Oei AL, Crezee J, Bel A, Franken NAP, Stalpers LJA, et al. The alfa and beta of tumours: a review of parameters of the linear-quadratic model, derived from clinical radiotherapy studies. Radiat Oncol 2018; 13: 96. doi: 10.1186\/s13014-018-1040-z","DOI":"10.1186\/s13014-018-1040-z"},{"key":"2026071216052977598_j_raon-2026-0008_ref_008","doi-asserted-by":"crossref","unstructured":"Brand DH, Kirby AM, Yarnold JR, Somaiah N. How low can you go? The radiobiology of hypofractionation. Clin Oncol (R Coll Radiol) 2022; 34: 280-7. doi: 10.1016\/j.clon.2022.02.009","DOI":"10.1016\/j.clon.2022.02.009"},{"key":"2026071216052977598_j_raon-2026-0008_ref_009","doi-asserted-by":"crossref","unstructured":"Haviland JS, Owen JR, Dewar JA, Agrawal RK, Barrett J, Barrett-Lee PJ, et al. The UK Standardisation of Breast Radiotherapy (START) trials: 10-year follow-up results of two randomised controlled trials. Lancet Oncol 2013; 14: 1086-94. doi: 10.1016\/S1470-2045(13)70386-3","DOI":"10.1016\/S1470-2045(13)70386-3"},{"key":"2026071216052977598_j_raon-2026-0008_ref_010","doi-asserted-by":"crossref","unstructured":"START Trialists\u2019 Group, Bentzen SM, Agrawal RK, Aird EG, Barrett JM, Barrett-Lee PJ, et al. The UK standardisation of breast radiotherapy (START) trial A of radiotherapy hypofractionation for treatment of early breast cancer: a randomised trial. Lancet Oncol 2008; 9: 331-41. doi: 10.1016\/S1470-2045(08)70077-9","DOI":"10.1016\/S1470-2045(08)70077-9"},{"key":"2026071216052977598_j_raon-2026-0008_ref_011","doi-asserted-by":"crossref","unstructured":"START Trialists\u2019 Group, Bentzen SM, Agrawal RK, Aird EG, Barrett JM, Barrett-Lee PJ, et al. The UK standardisation of breast radiotherapy (START) trial B of radiotherapy hypofractionation for treatment of early breast cancer: a randomised trial. Lancet 2008; 371: 1098-107. doi: 10.1016\/S0140-6736(08)60348-7","DOI":"10.1016\/S0140-6736(08)60348-7"},{"key":"2026071216052977598_j_raon-2026-0008_ref_012","doi-asserted-by":"crossref","unstructured":"Loibl S, Andr\u00e9 F, Bachelot T, Barrios CH, Bergh J, Burstein HJ, et al. Early breast cancer: ESMO clinical practice guideline for diagnosis, treatment and follow-up. Ann Oncol 2024; 35: 159-82. doi: 10.1016\/j.annonc.2023.11.016","DOI":"10.1016\/j.annonc.2023.11.016"},{"key":"2026071216052977598_j_raon-2026-0008_ref_013","doi-asserted-by":"crossref","unstructured":"Meattini I, Becherini C, Boersma L, Kaidar-Person O, Marta GN, Montero A, et al. European society for radiotherapy and oncology advisory committee in radiation oncology practice consensus recommendations on patient selection and dose and fractionation for external beam radiotherapy in early breast cancer. Lancet Oncol 2022; 23: e21-e31. doi: 10.1016\/S1470-2045(21)00539-8","DOI":"10.1016\/S1470-2045(21)00539-8"},{"key":"2026071216052977598_j_raon-2026-0008_ref_014","unstructured":"National Comprehensive Cancer Network. (2025). NCCN clinical practice guidelines in oncology (NCCN Guidelines\u00ae): Breast cancer (Version 3.2025). [cited 2025 Sep 15]. Available at: https:\/\/www.nccn.org\/professionals\/physician_gls\/pdf\/breast.pdf"},{"key":"2026071216052977598_j_raon-2026-0008_ref_015","doi-asserted-by":"crossref","unstructured":"FAST Trialists group, Agrawal RK, Alhasso A, Barrett-Lee PJ, Bliss JM, Bliss P, et al. First results of the randomised UK FAST Trial of radiotherapy hypofractionation for treatment of early breast cancer (CRUKE\/04\/015). Radiother Oncol 2011; 100: 93-100. doi: 10.1016\/j.radonc.2011.06.026","DOI":"10.1016\/j.radonc.2011.06.026"},{"key":"2026071216052977598_j_raon-2026-0008_ref_016","doi-asserted-by":"crossref","unstructured":"Murray Brunt A, Haviland JS, Sydenham M, Agrawal RK, Algurafi H, Alhasso A, et al. Ten-year results of FAST: A randomized controlled trial of 5-fraction whole-breast radiotherapy for early breast cancer. J Clin Oncol 2020; 38: 3261-72. doi: 10.1200\/JCO.19.02750","DOI":"10.1200\/JCO.19.02750"},{"key":"2026071216052977598_j_raon-2026-0008_ref_017","doi-asserted-by":"crossref","unstructured":"Murray Brunt A, Haviland JS, Wheatley DA, Sydenham MA, Alhasso A, Bloomfield DJ, et al. Hypofractionated breast radiotherapy for 1 week versus 3 weeks (FAST-Forward): 5-year efficacy and late normal tissue effects results from a multicentre, non-inferiority, randomised, phase 3 trial. Lancet 2020; 395: 1613-26. doi: 10.1016\/S0140-6736(20)30932-6","DOI":"10.1016\/S0140-6736(20)30932-6"},{"key":"2026071216052977598_j_raon-2026-0008_ref_018","doi-asserted-by":"crossref","unstructured":"Murray Brunt A, Cafferty F, Wheatley DA, Patel J, Sydenham MA, Kirby AM, et al. Hypofractionated breast radiotherapy for 1 week vs. 3 weeks: 10-year efficacy and late normal tissue effects in the FAST-Forward randomised trial. Radiother Oncol 2025; 206: S4429-S4430. doi: 10.1016\/S0167-8140(25)04201-X","DOI":"10.1016\/S0167-8140(25)04201-X"},{"key":"2026071216052977598_j_raon-2026-0008_ref_019","doi-asserted-by":"crossref","unstructured":"Ivanov O, Milovan\u010dev A, Petrovi\u0107 B, Prvulovi\u0107 Bunovi\u0107 N, Li\u010dina J, Bojovi\u0107 M, et al. Ultra-hypofractionated vs. moderate fractionated whole breast three dimensional conformal radiotherapy during the COVID-19 Pandemic. Medicina (Kaunas) 2022; 58: 745. doi: 10.3390\/medicina58060745","DOI":"10.3390\/medicina58060745"},{"key":"2026071216052977598_j_raon-2026-0008_ref_020","doi-asserted-by":"crossref","unstructured":"Ratosa I, Montero A, Ciervide R, Alvarez B, Garcia Aranda M, Valero Albarr\u00e1n J, et al. Ultra-hypofractionated one-week locoregional radiation for early breast cancer: dose distribution to target volumes and organs-at-risk. Int J Radiat Oncol Biol Phys 2024; 120: e329-e30. doi: 10.1016\/j. ijrobp.2024.07.726","DOI":"10.1016\/j.ijrobp.2024.07.726"},{"key":"2026071216052977598_j_raon-2026-0008_ref_021","doi-asserted-by":"crossref","unstructured":"Oonsiri P, Nantavithya C, Lertbutsayanukul C, Sarsitthithum T, Vimolnoch M, Tawonwong T, et al. Dosimetric evaluation of photons versus protons in postmastectomy planning for ultrahypofractionated breast radiotherapy. Radiat Oncol 2022; 17: 20. doi: 10.1186\/s13014-022-01992-w","DOI":"10.1186\/s13014-022-01992-w"},{"key":"2026071216052977598_j_raon-2026-0008_ref_022","doi-asserted-by":"crossref","unstructured":"Kiesl S, D\u00fcsberg M, Behzadi ST, Moser R, Nano J, Huber T, et al. The impact of fractionation on secondary malignancies in postoperative breast cancer irradiation. Breast 2024; 78: 103819. doi: 10.1016\/j.breast.2024.103819","DOI":"10.1016\/j.breast.2024.103819"},{"key":"2026071216052977598_j_raon-2026-0008_ref_023","doi-asserted-by":"crossref","unstructured":"Schneider U, Sumila M, Robotka J. Site-specific dose-response relationships for cancer induction from the combined Japanese A-bomb and Hodgkin cohorts for doses relevant to radiotherapy. Theor Biol Med Model 2011; 8: 27. doi: 10.1186\/1742-4682-8-27","DOI":"10.1186\/1742-4682-8-27"},{"key":"2026071216052977598_j_raon-2026-0008_ref_024","doi-asserted-by":"crossref","unstructured":"De Rose F, De Santis MC, Lucidi S, Colciago RR, Marino L, Cucciarelli F, et al. Dose constraints in breast cancer radiotherapy. A critical review. Radiother Oncol 2025; 202: 110591. doi: 10.1016\/j.radonc.2024.110591","DOI":"10.1016\/j.radonc.2024.110591"},{"key":"2026071216052977598_j_raon-2026-0008_ref_025","doi-asserted-by":"crossref","unstructured":"Brunt AM, Haviland JS, Kirby AM, Somaiah N, Wheatley DA, Bliss JM, et al. Five-fraction radiotherapy for breast cancer: FAST-Forward to Implementation. Clin Oncol (R Coll Radiol) 2021; 33: 430-9. doi: 10.1016\/j. clon.2021.04.016","DOI":"10.1016\/j.clon.2021.04.016"},{"key":"2026071216052977598_j_raon-2026-0008_ref_026","doi-asserted-by":"crossref","unstructured":"Busschaert SL, Kimpe E, Barb\u00e9 K, De Ridder M, Putman K. Introduction of ultra-hypofractionation in breast cancer: implications for costs and resource use. Radiother Oncol 2024; 190: 110010. doi: 10.1016\/j.ra-donc.2023.110010","DOI":"10.1016\/j.radonc.2023.110010"}],"container-title":["Radiology and Oncology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/reference-global.com\/pdf\/10.2478\/raon-2026-0008","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,7,13]],"date-time":"2026-07-13T00:02:50Z","timestamp":1783900970000},"score":1,"resource":{"primary":{"URL":"https:\/\/reference-global.com\/article\/10.2478\/raon-2026-0008"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,2,6]]},"references-count":26,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2026,2,6]]},"published-print":{"date-parts":[[2026,3,1]]}},"alternative-id":["10.2478\/raon-2026-0008"],"URL":"https:\/\/doi.org\/10.2478\/raon-2026-0008","relation":{},"ISSN":["1581-3207"],"issn-type":[{"value":"1581-3207","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,2,6]]}}}